292 related articles for article (PubMed ID: 37147419)
1. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma.
Lucas MW; Versluis JM; Rozeman EA; Blank CU
Nat Rev Clin Oncol; 2023 Jun; 20(6):408-422. PubMed ID: 37147419
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.
Sarver M; Brown MC; Rhodin KE; Salama AKS; Beasley GM
Hum Vaccin Immunother; 2022 May; 18(3):1943987. PubMed ID: 34254900
[TBL] [Abstract][Full Text] [Related]
4. Educational Review: Neoadjuvant Approaches to Melanoma.
Sharon CE; Karakousis GC
Ann Surg Oncol; 2022 Dec; 29(13):8492-8500. PubMed ID: 35849287
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
Ferraresi V; Vari S
Hum Vaccin Immunother; 2022 May; 18(3):1971015. PubMed ID: 34882516
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors in melanoma.
Carlino MS; Larkin J; Long GV
Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
[TBL] [Abstract][Full Text] [Related]
8. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing.
van Akkooi ACJ; Zijlker LP; Wouters MWJM
BioDrugs; 2022 May; 36(3):373-380. PubMed ID: 35397089
[TBL] [Abstract][Full Text] [Related]
10. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
McKean MA; Amaria RN
Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
12. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Huang AC; Orlowski RJ; Xu X; Mick R; George SM; Yan PK; Manne S; Kraya AA; Wubbenhorst B; Dorfman L; D'Andrea K; Wenz BM; Liu S; Chilukuri L; Kozlov A; Carberry M; Giles L; Kier MW; Quagliarello F; McGettigan S; Kreider K; Annamalai L; Zhao Q; Mogg R; Xu W; Blumenschein WM; Yearley JH; Linette GP; Amaravadi RK; Schuchter LM; Herati RS; Bengsch B; Nathanson KL; Farwell MD; Karakousis GC; Wherry EJ; Mitchell TC
Nat Med; 2019 Mar; 25(3):454-461. PubMed ID: 30804515
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Therapies for Melanoma.
Buchbinder EI
Hematol Oncol Clin North Am; 2021 Feb; 35(1):99-109. PubMed ID: 33759776
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
Rohaan MW; Stahlie EHA; Franke V; Zijlker LP; Wilgenhof S; van der Noort V; van Akkooi ACJ; Haanen JBAG
BMC Cancer; 2022 Aug; 22(1):851. PubMed ID: 35927710
[TBL] [Abstract][Full Text] [Related]
15. The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.
Stege H; Haist M; Nikfarjam U; Schultheis M; Heinz J; Pemler S; Loquai C; Grabbe S
Target Oncol; 2021 Sep; 16(5):537-552. PubMed ID: 34554353
[TBL] [Abstract][Full Text] [Related]
16. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
Versluis JM; Menzies AM; Sikorska K; Rozeman EA; Saw RPM; van Houdt WJ; Eriksson H; Klop WMC; Ch'ng S; van Thienen JV; Mallo H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; van der Wal A; Bruining A; van de Wiel BA; Scolyer RA; Haanen JBAG; Schumacher TN; van Akkooi ACJ; Long GV; Blank CU
Ann Oncol; 2023 Apr; 34(4):420-430. PubMed ID: 36681299
[TBL] [Abstract][Full Text] [Related]
17. Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors.
Hooiveld-Noeken JS; Eggen AC; Rácz E; de Vries EGE; Reyners AKL; Jalving M
Crit Rev Oncol Hematol; 2022 Dec; 180():103855. PubMed ID: 36257534
[TBL] [Abstract][Full Text] [Related]
18. Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?
Adileh M; Yuval JB; Huang S; Shoushtari AN; Quezada-Diaz F; Pappou EP; Weiser MR; Garcia-Aguilar J; Smith JJ; Paty PB; Nash GM
Dis Colon Rectum; 2021 May; 64(5):555-562. PubMed ID: 33939387
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma.
Song Y; Straker RJ; Xu X; Elder DE; Gimotty PA; Huang AC; Mitchell TC; Amaravadi RK; Schuchter LM; Karakousis GC
Ann Surg Oncol; 2020 Aug; 27(8):2915-2926. PubMed ID: 31898103
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.
Hieken TJ; Kreidieh F; Aedo-Lopez V; Block MS; McArthur GA; Amaria RN
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390614. PubMed ID: 37116111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]